Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Common Equity (2016 - 2025)

Ultragenyx Pharmaceutical has reported Common Equity over the past 11 years, most recently at -$80.0 million for Q4 2025.

  • Quarterly Common Equity fell 131.37% to -$80.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$80.0 million through Dec 2025, down 131.37% year-over-year, with the annual reading at -$80.0 million for FY2025, 131.37% down from the prior year.
  • Common Equity was -$80.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $9.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $1.1 billion in Q1 2021 and troughed at -$80.0 million in Q4 2025.
  • The 5-year median for Common Equity is $310.9 million (2023), against an average of $411.7 million.
  • Year-over-year, Common Equity skyrocketed 993.61% in 2024 and then crashed 131.37% in 2025.
  • A 5-year view of Common Equity shows it stood at $922.6 million in 2021, then crashed by 61.85% to $352.0 million in 2022, then decreased by 21.88% to $275.0 million in 2023, then dropped by 7.27% to $255.0 million in 2024, then tumbled by 131.37% to -$80.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Common Equity are -$80.0 million (Q4 2025), $9.2 million (Q3 2025), and $151.3 million (Q2 2025).